Lafayette Investments Inc. Trims Stock Position in Enovis Co. (NYSE:ENOV)

Lafayette Investments Inc. lowered its holdings in shares of Enovis Co. (NYSE:ENOV) by 10.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 29,832 shares of the company’s stock after selling 3,595 shares during the quarter. Lafayette Investments Inc.’s holdings in Enovis were worth $1,671,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ENOV. UMB Bank n.a. purchased a new stake in Enovis in the 3rd quarter worth approximately $31,000. Fifth Third Bancorp increased its holdings in Enovis by 144.6% in the 3rd quarter. Fifth Third Bancorp now owns 587 shares of the company’s stock worth $31,000 after acquiring an additional 347 shares in the last quarter. State of Wyoming increased its holdings in Enovis by 59,200.0% in the 4th quarter. State of Wyoming now owns 593 shares of the company’s stock worth $32,000 after acquiring an additional 592 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in Enovis by 902.7% in the 3rd quarter. First Horizon Advisors Inc. now owns 732 shares of the company’s stock worth $39,000 after acquiring an additional 659 shares in the last quarter. Finally, Lazard Asset Management LLC purchased a new stake in Enovis in the 4th quarter worth approximately $63,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on ENOV. Stephens began coverage on Enovis in a research note on Tuesday, February 13th. They issued an “overweight” rating and a $72.00 price target for the company. William Blair began coverage on Enovis in a research note on Wednesday, January 3rd. They issued an “outperform” rating for the company. Needham & Company LLC restated a “buy” rating and issued a $82.00 price target on shares of Enovis in a research note on Wednesday, April 10th. Wells Fargo & Company upped their price target on Enovis from $73.00 to $79.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Finally, UBS Group began coverage on Enovis in a research note on Monday, January 22nd. They issued a “buy” rating and a $75.00 price target for the company. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $75.43.

Enovis Trading Up 1.2 %

Shares of NYSE ENOV traded up $0.65 during midday trading on Friday, reaching $55.92. 70,460 shares of the stock traded hands, compared to its average volume of 446,443. The company has a quick ratio of 1.16, a current ratio of 2.43 and a debt-to-equity ratio of 0.14. Enovis Co. has a one year low of $43.04 and a one year high of $66.14. The company’s 50 day moving average is $60.38 and its 200 day moving average is $55.29.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, February 22nd. The company reported $0.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.76 by $0.03. The company had revenue of $455.00 million during the quarter, compared to the consensus estimate of $444.34 million. Enovis had a positive return on equity of 3.84% and a negative net margin of 1.95%. Enovis’s revenue was up 11.2% on a year-over-year basis. During the same period last year, the company earned $0.72 earnings per share. On average, research analysts anticipate that Enovis Co. will post 2.58 EPS for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.